Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma

Abstract

HCC patients with ARID1A mutation may benefit from synthetic lethal therapy targeting the ubiquitin-specific peptidase 9 X-linked (USP9X)-adenosine 5'-monophosphate-activated protein kinase (AMPK) axis.